Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002450 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
NCT00002450: Completed Phase 3 study, sponsored by Gilead Sciences.
NCT00002450 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 600 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002450, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
Study Summary
The purpose of this study is to see if giving tenofovir DF plus a combination of other anti-HIV drugs is safe and effective.
Interventions
- DRUG Tenofovir disoproxil fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Phase | Phase 3 |
What the finished NCT00002450 record still lists
NCT00002450 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower).
The record links to 0 conditions, and to 1 intervention - of which Tenofovir disoproxil fumarate is the first listed.
NCT00002450 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002450 about?
NCT00002450 is a clinical study titled "Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients". The purpose of this study is to see if giving tenofovir DF plus a combination of other anti-HIV drugs is safe and effective.
What is the current status of trial NCT00002450?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 600 participants.
What interventions are being tested in trial NCT00002450?
The interventions under investigation include: Tenofovir disoproxil fumarate (DRUG).
Who is sponsoring clinical trial NCT00002450?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002450's enrollment target sits among peer trials
600 608th of 2000 higher than 1,363 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging